Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.

  • Authors : Zaleska J; Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.; Department of Hematology, St John's Cancer Centre, Lublin, Poland.

Subjects: BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/immunology

  • Source: International journal of cancer [Int J Cancer] 2023 Feb 15; Vol. 152 (4), pp. 705-712. Date of Electronic Publication: 2022 Jul 27.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey.

  • Authors : Çağlayan D; Department of Public Health, Division of Epidemiology, School of Medicine, Dokuz Eylül University, Izmir, Turkey.; Süner AF

Subjects: BNT162 Vaccine* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Antibodies, Viral

  • Source: Journal of medical virology [J Med Virol] 2022 May; Vol. 94 (5), pp. 2212-2221. Date of Electronic Publication: 2022 Feb 03.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Antibody response 6 months after the booster dose of Pfizer in previous recipients of CoronaVac.

Subjects: Antibody Formation* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Humans

  • Source: Journal of medical virology [J Med Virol] 2023 Jan; Vol. 95 (1), pp. e28169. Date of Electronic Publication: 2022 Oct 01.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

×
Editorial & Opinion

Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID-19 vaccine.

  • Authors : Kozawa K; Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.; Miura H

Subjects: Antibody Formation* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Antibodies, Viral

  • Source: Journal of medical virology [J Med Virol] 2022 Oct; Vol. 94 (10), pp. 4583-4585. Date of Electronic Publication: 2022 Jun 09.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.

  • Authors : Woo W; Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Kim AY

Subjects: 2019-nCoV Vaccine mRNA-1273/2019-nCoV Vaccine mRNA-1273/2019-nCoV Vaccine mRNA-1273/*adverse effects ; BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*adverse effects ; COVID-19/COVID-19/COVID-19/*prevention & control

  • Source: Journal of medical virology [J Med Virol] 2022 Apr; Vol. 94 (4), pp. 1566-1580. Date of Electronic Publication: 2021 Dec 14.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.

  • Authors : Almanzar G; Department of Pediatrics, Pediatric Rheumatology/Special Immunology, University Hospital Würzburg, Würzburg, Germany.; Koosha K

Subjects: COVID-19*/COVID-19*/COVID-19*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; Antibodies, Viral*/Antibodies, Viral*/Antibodies, Viral*/blood COVID-19 breakthrough infections

  • Source: Journal of medical virology [J Med Virol] 2024 Jun; Vol. 96 (6), pp. e29739.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination.

  • Authors : Mele D; Division of Clinical Immunology - Infectious Diseases, Department of Research, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; Ottolini S

Subjects: COVID-19 Vaccines* ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; Spike Glycoprotein, Coronavirus*

  • Source: Journal of medical virology [J Med Virol] 2024 Apr; Vol. 96 (4), pp. e29585.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Comparable CD8 + T-cell responses to SARS-CoV-2 vaccination in single-cell transcriptomics of recently allogeneic transplanted patients and healthy individuals.

  • Authors : Tranter E; Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Frentsch M

Subjects: COVID-19* ; Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/adverse effects; Humans

  • Source: Journal of medical virology [J Med Virol] 2024 Mar; Vol. 96 (3), pp. e29539.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.

  • Authors : Zedan HT; Infectious Diseases Department, Biomedical Research Center, Research Complex, Qatar University, Doha, Qatar.; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.

Subjects: COVID-19 Vaccines* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Humans SARS-CoV-2 variants

  • Source: Journal of medical virology [J Med Virol] 2024 Mar; Vol. 96 (3), pp. e29527.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong.

  • Authors : Luo J; Vincent V.C. Woo Chinese Medicine Clinical Research Institute, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.; Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.

Subjects: Post-Acute COVID-19 Syndrome* ; COVID-19*/COVID-19*/COVID-19*/epidemiology; Middle Aged SARS-CoV-2 variants

  • Source: Journal of medical virology [J Med Virol] 2023 Jun; Vol. 95 (6), pp. e28862.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

×
  • 1-10 of  46 results for ""BNT162 Vaccine""